1) Ian F. Tannock, Richard P. Hill, Robert G. Bristow LH. Basic Science of Oncology. (McGraw-Hill Education).
2) Hodi FS, O’Day SJ, McDermott DF, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N. Engl. J. Med. 363: 711–723, 2010.
3) Topalian SL, Hodi FS, Brahmer JR, et al. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer. N. Engl. J. Med. 366: 2443–2454, 2012.
4) Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer. N. Engl. J. Med. 373: 123–135, 2015.
5) Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 373: 1803–1813, 2015.
6) Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515: 558–562, 2014.
7) Hamanishi J, Mandai M, Ikeda T, et al. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. J. Clin. Oncol. 33: 4015–22, 2015.
8) Gibson J. Anti-PD-L1 for metastatic triple-negative breast cancer. Lancet Oncol. 16: e264, 2015.
9) Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet. Oncol. 17: 717–26, 2016.
10) Ribas A & Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 359: 1350–1355, 2018.
11) Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348: 124–8, 2015.
12) Snyder A, Makarov V, Merghoub T, et al. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. N. Engl. J. Med. 371: 2189–2199, 2014.
13) Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515: 568–71, 2014.
14) Kato D, Yaguchi T, Iwata T, et al. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies. Japanese J. Clin. Immunol. 40: 68–77, 2017.
15) Maude SL, Frey N, Shaw PA, et al. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N. Engl. J. Med. 371: 1507–1517, 2014.
16) Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 385: 517–28, 2015.
17) Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18: 843–51, 2010.
18) Klebanoff CA, Rosenberg SA & Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat. Med. 22: 26–36, 2016.
19) Yaguchi T & Kawakami Y. Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation. Int. Immunol. 28: 393–9, 2016.
20) Albini A & Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat. Rev. Cancer 7: 139–147, 2007.
21) Jen Y-HL, Musacchio M & Lander AD. Glypican-1 controls brain size through regulation of fibroblast growth factor signaling in early neurogenesis. Neural Dev. 4: 33, 2009.
22) Hara H, Takahashi T, Serada S, et al. Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma. Br. J. Cancer 115: 66–75, 2016.
23) Duan L, Hu X, Feng D, et al. GPC-1 may serve as a predictor of perineural invasion and a prognosticator of survival in pancreatic cancer. Asian J. Surg. 36: 7–12, 2013.
24) Melo SA, Luecke LB, Kahlert C, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 523: 177–182, 2015.
25) Su G, Meyer K, Nandini CD, et al. Glypican-1 is frequently overexpressed in human gliomas and enhances FGF-2 signaling in glioma cells. Am. J. Pathol. 168: 2014–26, 2006.
26) Amatya VJ, Kushitani K, Kai Y, et al. Glypican-1 immunohistochemistry is a novel marker to differentiate epithelioid mesothelioma from lung adenocarcinoma. Mod. Pathol. 31: 809–815, 2018.
27) Matsuda K, Maruyama H, Guo F, et al. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res. 61: 5562–9, 2001.
28) Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. U. S. A. 99: 12293–7, 2002.
29) Harada E, Serada S, Fujimoto M, et al. Glypican-1 targeted antibody-based therapy induces preclinical antitumor activity against esophageal squamous cell carcinoma. Oncotarget 8: 24741–24752, 2017.
30) Matsuzaki S, Serada S, Hiramatsu K, et al. Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer. Int. J. cancer 142: 1056–1066, 2018.
31) Siegler EL & Wang P. Preclinical Models in Chimeric Antigen Receptor– Engineered T-Cell Therapy. Hum. Gene Ther. 29: 534–546, 2018.
32) Delahaut P. Immunisation – Choice of host, adjuvants and boosting schedules with emphasis on polyclonal antibody production. Methods 116: 4–11, 2017.
33) Walker AJ, Majzner RG, Zhang L, et al. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase. Mol. Ther. 25: 2189–2201, 2017.
34) James SE, Greenberg PD, Jensen MC, et al. Mathematical Modeling of Chimeric TCR Triggering Predicts the Magnitude of Target Lysis and Its Impairment by TCR Downmodulation. J. Immunol. 184: 4284–4294, 2010.
35) Hollyman D, Stefanski J, Przybylowski M, et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J. Immunother. 32: 169–80, 2009.
36) Gross G, Waks T & Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl. Acad. Sci. U. S. A. 86: 10024–8, 1989.
37) Morsut L, Roybal KT, Xiong X, et al. Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. Cell 164: 780–91, 2016.
38) Wu C-Y, Roybal KT, Puchner EM, et al. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science (80-. ). 350: aab4077-aab4077, 2015.
39) Zhong X-S, Matsushita M, Plotkin J, et al. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol. Ther. 18: 413–20, 2010.
40) Zhao Y, Wang QJ, Yang S, et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J. Immunol. 183: 5563–74, 2009.
41) Milone MC, Fish JD, Carpenito C, et al. Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo. Mol. Ther. 17: 1453–1464, 2009.
42) Lim WA & June CH. The Principles of Engineering Immune Cells to Treat Cancer. Cell 168: 724–740, 2017.
43) Gao H, Li K, Tu H, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin. Cancer Res. 20: 6418–28, 2014.
44) Kishton RJ, Sukumar M & Restifo NP. Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. Cell Metab. 26: 94–109, 2017.
45) Gurusamy D, Clever D, Eil R, et al. Novel “Elements” of Immune Suppression within the Tumor Microenvironment. Cancer Immunol. Res. 5: 426–433, 2017.
46) Eil R, Vodnala SK, Clever D, et al. Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature 537: 539–543, 2016.
47) Liu M, Wang X, Wang L, et al. Targeting the IDO1 pathway in cancer: from bench to bedside. J. Hematol. Oncol. 11: 100, 2018.
48) Mellor AL & Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4: 762–74, 2004.
49) Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. U. S. A. 106: 3360–5, 2009.
50) Hudecek M, Lupo-Stanghellini M-T, Kosasih PL, et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin. Cancer Res. 19: 3153–64, 2013.
51) Jensen MC & Riddell SR. Designing chimeric antigen receptors to effectively and safely target tumors. Curr. Opin. Immunol. 33: 9–15, 2015.
52) Rosenberg SA & Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 348: 62–68, 2015.
53) Chen DS & Mellman I. Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity 39: 1–10, 2013.
54) Anderson AC, Joller N & Kuchroo VK. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity 44: 989– 1004, 2016.
55) Sharma P & Allison JP. Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential. Cell 161: 205–214, 2015.
56) Yaguchi T, Sumimoto H, Kudo-Saito C, et al. The mechanisms of cancer immunoescape and development of overcoming strategies. Int. J. Hematol. 93: 294–300, 2011.
57) Yaguchi T, Goto Y, Kido K, et al. Immune suppression and resistance mediated by constitutive activation of Wnt/β-catenin signaling in human melanoma cells. J. Immunol. 189: 2110–7, 2012.
58) Zelenay S, van der Veen AG, Böttcher JP, et al. Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell 162: 1257–70, 2015.
59) Iwai Y, Hamanishi J, Chamoto K, et al. Cancer immunotherapies targeting the PD-1 signaling pathway. J. Biomed. Sci. 24: 26, 2017.
60) Chinnasamy D, Yu Z, Theoret MR, et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J. Clin. Invest. 120: 3953–3968, 2010.
61) Tran E, Chinnasamy D, Yu Z, et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J. Exp. Med. 210: 1125–35, 2013.
62) Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118: 6050–6, 2011.
63) Brown CE, Alizadeh D, Starr R, et al. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N. Engl. J. Med. 375: 2561–2569, 2016.
64) Beatty GL, Haas AR, Maus M V., et al. Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies. Cancer Immunol. Res. 2: 112–120, 2014.
65) Busch DH, Fräßle SP, Sommermeyer D, et al. Role of memory T cell subsets for adoptive immunotherapy. Semin. Immunol. 28: 28–34, 2016.
66) Gattinoni L, Klebanoff CA & Restifo NP. Paths to stemness: building the ultimate antitumour T cell. Nat. Rev. Cancer 12: 671–684, 2012.
67) Beatty GL, Haas AR, Maus M V, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol. Res. 2: 112–20, 2014.
68) Kamphorst AO, Wieland A, Nasti T, et al. Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent. Science. 355: 1423–1427, 2017.
69) Hui E, Cheung J, Zhu J, et al. T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition. Science. 355: 1428–1433, 2017.
70) Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24: 563–571, 2018.
71) O’Rourke DM, Nasrallah MP, Desai A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. 9: eaaa0984, 2017.